Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercia…
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercia…
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of…
KYAN Technologies, a vanguard combinatory drug development solutions provider, is thrilled to announce a strategic partn…
Avantra, the industry leading AIOps platform for SAP operations automation, announced the upcoming release of its Avantr…
Straumann Group to acquire AlliedStar to complement its intraoral scanner portfolio across different price points and ex…
Capital Markets Day 2023 will be hosted by members of the Lonza Executive Committee The presentation will provide an ove…
CEO Pierre-Alain Ruffieux to leave Lonza Albert M. Baehny to step in as CEO ad interim Capital Markets Day on October 17…
Half-year revenue reached CHF 1.2 billion, growing 7.5% organically, achieving CHF 621 million or 11.7% in the second qu…
Straumann Group announces that its Chairman Gilbert Achermann has decided not to seek re-election as Chairman and Board…
In H1 2023, Lonza delivered CHF 3.1 billion sales and 5.6% CER1 sales growth, corresponding to around 10% CER underlying…